Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study

Página do item simplificado
dc.contributor.authorde Souza, Letícia Rodrigues
dc.contributor.authorMagro, Daniela Oliveira
dc.contributor.authorTeixeira, Fábio Vieira
dc.contributor.authorParra, Rogério Serafim
dc.contributor.authorMiranda, Eron Fábio
dc.contributor.authorFéres, Omar
dc.contributor.authorSaad-Hossne, Rogério [UNESP]
dc.contributor.authorSoares Prates Herrerias, Giedre [UNESP]
dc.contributor.authorNisihara, Renato Mitsunori
dc.contributor.authorCoy, Claudio Saddy Rodrigues
dc.contributor.authorSassaki, Ligia Yukie [UNESP]
dc.contributor.authorKotze, Paulo Gustavo
dc.contributor.institutionPUCPR
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.contributor.institutionClínica Gastrosaúde
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionMackenzie Evangelical School of Medicine
dc.date.accessioned2023-07-29T16:07:10Z
dc.date.available2023-07-29T16:07:10Z
dc.date.issued2023-02-01
dc.description.abstractDespite some variability in ideal serum Adalimumab (ADA) concentrations, there is increasing evidence that higher concentrations of anti-TNF-α agents can be associated with sustained efficacy, and low or undetectable levels may lead to loss of response. This study aims to correlate serum ADA concentrations with clinical and endoscopic activity in patients with Crohn’s disease (CD). A cross-sectional and multicentric study was performed with patients with CD, who used ADA for at least 24 weeks. Patients were allocated into groups according to the presence of clinical or endoscopic disease activity. Serum ADA concentrations were measured and compared between groups. Overall, 89 patients were included. A total of 27 patients had clinically active CD and 62 were in clinical remission. Forty patients had endoscopic disease activity and 49 were in endoscopic remission. The mean serum ADA concentration was 10.2 μg/mL in patients with clinically active CD and 14.3 μg/mL in patients in clinical remission (p = 0.395). The mean serum ADA concentration in patients with endoscopic activity was 11.3 μg/mL as compared to 14.5 μg/mL in those with endoscopic remission (p = 0.566). There was no difference between serum ADA concentrations regarding clinical or endoscopic activity in CD, as compared to patients in remission.en
dc.description.affiliationColorectal Surgery Unit Pontificia Universidade Católica do Paraná PUCPR
dc.description.affiliationColorectal Surgery Unit Universidade Estadual de Campinas UNICAMP
dc.description.affiliationClínica Gastrosaúde
dc.description.affiliationColorectal Surgery Unit Universidade de São Paulo USP
dc.description.affiliationIBD Outpatient Clinics São Paulo State University UNESP
dc.description.affiliationDepartment of Immunology Mackenzie Evangelical School of Medicine
dc.description.affiliationUnespIBD Outpatient Clinics São Paulo State University UNESP
dc.identifierhttp://dx.doi.org/10.3390/pharmaceutics15020586
dc.identifier.citationPharmaceutics, v. 15, n. 2, 2023.
dc.identifier.doi10.3390/pharmaceutics15020586
dc.identifier.issn1999-4923
dc.identifier.scopus2-s2.0-85149141356
dc.identifier.urihttp://hdl.handle.net/11449/249712
dc.language.isoeng
dc.relation.ispartofPharmaceutics
dc.sourceScopus
dc.subjectadalimumab
dc.subjectCrohn’s disease
dc.subjectdosage
dc.subjectinflammatory bowel diseases
dc.subjecttherapeutic drug monitoring
dc.titleAdalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Studyen
dc.typeArtigo
unesp.author.orcid0000-0003-1916-813X[1]
unesp.author.orcid0000-0002-8180-6254[2]
unesp.author.orcid0000-0002-5566-9284[4]
unesp.author.orcid0000-0003-4011-5112[5]
unesp.author.orcid0000-0002-7319-8906[11]
unesp.author.orcid0000-0002-9632-6691[12]

Arquivos

Coleções

Artigos - Cirurgia e Ortopedia - FMB